HIER Corporation Secures Strategic Investment from Amorepacific Holdings to Strengthen Beauty-Medical Collaboration

HIER Corporation, a specialist in aesthetic medical devices, has entered into a strategic investment agreement with Amorepacific Holdings to advance collaboration in the beauty-medical sector. The partnership aims to bridge the gap between professional clinical treatments and daily skincare through joint research and development of next-generation medical solutions. This move highlights a growing trend of convergence between traditional dermatological science and advanced medical device technology within the global aesthetics market.

Under the terms of the agreement announced on July 27, Amorepacific Holdings has made a strategic investment of an undisclosed amount in HIER Corporation to foster a mid- to long-term partnership. The collaboration will integrate HIER Corporation’s expertise in aesthetic medical device development and its extensive network of global key opinion leaders (KOLs) with Amorepacific’s established dermatological research and brand assets. The two entities plan to cooperate across the entire value chain, including product planning, research and development, distribution, and marketing, to create integrated solutions for the global beauty-medical market.

The joint venture will specifically focus on the development and commercialization of skin beauty products such as skin boosters, cosmeceuticals, and specialized medical devices. Additionally, the companies intend to collaborate on post-treatment after-care products and leverage hospital and clinic distribution channels. Research efforts will also extend to the development of new raw materials and ingredients, aiming to provide a seamless transition between professional medical procedures and everyday skincare routines. This synergy is expected to enhance the clinical evidence base for new treatments while expanding the reach of both companies in the medical aesthetics space.

Founded in 2021, HIER Corporation has rapidly expanded its footprint in the aesthetic medical device market, currently operating in South Korea, Japan, Indonesia, and Vietnam. The company’s flagship product, HILO WAVE, is a Dual-HA-based collagen booster that utilizes high-molecular and low-molecular hyaluronic acid for regeneration-focused skin remodeling. According to HIER Corporation CEO Kim In-yong, the partnership with Amorepacific represents a significant milestone in combining clinical aesthetic expertise with advanced dermatological science. Amorepacific Holdings CEO Lee Sang-mok added that the collaboration is designed to deliver innovative customer experiences by merging medical device technology with dermatological research.